Saturday, September 26, 2020

why Corcept Therapeutics Incorporated [CORT] is a Good Choice for Investors After New Price Target of $16.75

Must read

Market cap of QEP Resources Inc. [QEP] reaches 252.19M – now what?

QEP Resources Inc. plunged by -$0.07 during the normal trading session on Monday and reaching a high of $1.08 during the day while...

Market cap of Aehr Test Systems [AEHR] reaches 33.56M – now what?

Aehr Test Systems stock went on a downward path that fall over -0.69% on Thursday, amounting to a one-week price decrease of less...

First American Financial Corporation [FAF] moved down -1.24: Why It’s Important

First American Financial Corporation loss -1.24% on the last trading session, reaching $50.25 price per share at the time. First American Financial Corporation...

Summit Materials Inc. [SUM] Stock trading around $15.66 per share: What’s Next?

Summit Materials Inc. gained 2.15% or 0.33 points to close at $15.66 with a heavy trading volume of 1352043 shares. It opened the...

Corcept Therapeutics Incorporated [NASDAQ: CORT] jumped around 0.9 points on Friday, while shares priced at $19.98 at the close of the session, up 4.72%. The company report on August 5, 2020 that Shuman Glenn & Stecker Investigates Corcept Therapeutics, Inc..

Shuman Glenn & Stecker announces that it is investigating potential shareholder claims against certain officers and directors of Corcept Therapeutics, Inc. (“Corcept” or the “Company”) (Nasdaq: CORT). Corcept is a pharmaceutical company.

The Firm’s investigation relates to allegations raised in a January 25, 2019 report by the nonprofit Foundation for Financial Journalism (“FFJ”) titled “Corcept Therapeutics: The Company That Perfectly Explains the Health Care Crisis”. In its report, FFJ alleged a Company-wide “off-label” marketing scheme involving a Corcept drug called Korlym. FFJ further alleged that increasing deaths had been associated with the drug. Korlym is not approved by the FDA for general treatment of endogenous Cushing’s Syndrome, a rare disease affecting approximately 20,000 Americans. Rather, Korlym has only been FDA-approved for treatment of a tiny fraction of Cushing’s Syndrome patients who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. FFJ alleged, however, that pursuant to Corcept’s “off-label” marketing scheme, physicians were induced via honoraria and speaker payments to prescribe Korlym for general treatment of Cushing’s Syndrome. Less than a week after the FFJ report was published, on January 31, 2019, Corcept forecasted a slowdown in Korlym sales, projecting full-year 2019 revenues which were well below analysts’ expectations. As a result, Corcept’s stock price dropped by over 10% on February 1, 2019. A federal securities fraud class action against Corcept was subsequently filed on March 14, 2019 in the U.S. District Court for the Northern District of California. That case remains pending.

Corcept Therapeutics Incorporated stock is now 65.12% up from its year-to-date (YTD) trading value. CORT Stock saw the intraday high of $20.44 and lowest of $18.75 per share. The company’s 52-week high price is 23.48, which means current price is +105.98% above from all time high which was touched on 09/02/20.

Compared to the average trading volume of 2.59M shares, CORT reached a trading volume of 4997666 in the most recent trading day, which is why market watchdogs consider the stock to be active.

What do top market gurus say about Corcept Therapeutics Incorporated [CORT]?

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for CORT shares is $16.75 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on CORT stock is a recommendation set at 2.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Jefferies have made an estimate for Corcept Therapeutics Incorporated shares, keeping their opinion on the stock as Hold, with their previous recommendation back on August 05, 2020. While these analysts kept the previous recommendation, Jefferies raised their target price to Buy. The new note on the price target was released on September 24, 2019, representing the official price target for Corcept Therapeutics Incorporated stock. Previously, the target price had yet another raise to $18, while H.C. Wainwright analysts kept a Buy rating on CORT stock. On February 04, 2019, analysts decreased their price target for CORT shares from 22 to 12.

The Average True Range (ATR) for Corcept Therapeutics Incorporated is set at 1.40, with the Price to Sales ratio for CORT stock in the period of the last 12 months amounting to 6.28. The Price to Book ratio for the last quarter was 5.07, with the Price to Cash per share for the same quarter was set at 3.67. Price to Free Cash Flow for CORT in the course of the last twelve months was 12.76 with Quick ratio for the last quarter at 10.30.

How has CORT stock performed recently?

Corcept Therapeutics Incorporated [CORT] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 58.45. With this latest performance, CORT shares gained by 43.02% in over the last four-week period, additionally plugging by 85.17% over the last 6 months – not to mention a rise of 57.45% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for CORT stock in for the last two-week period is set at 75.10, with the RSI for the last a single of trading hit 80.93, and the three-weeks RSI is set at 70.66 for Corcept Therapeutics Incorporated [CORT]. The present Moving Average for the last 50 days of trading for this stock 15.37, while it was recorded at 16.83 for the last single week of trading, and 13.66 for the last 200 days.

Corcept Therapeutics Incorporated [CORT]: Deeper insight into the fundamentals

Operating Margin for any stock indicates how profitable investing would be, and Corcept Therapeutics Incorporated [CORT] shares currently have an operating margin of +36.41 and a Gross Margin at +98.20. Corcept Therapeutics Incorporated’s Net Margin is presently recorded at +30.73.

Return on Total Capital for CORT is now 34.31, given the latest momentum, and Return on Invested Capital for the company is 29.02. Return on Equity for this stock inclined to 29.11, with Return on Assets sitting at 26.02. When it comes to the capital structure of this company, Corcept Therapeutics Incorporated [CORT] has a Total Debt to Total Equity ratio set at 0.93. Additionally, CORT Total Debt to Total Capital is recorded at 0.92, with Total Debt to Total Assets ending up at 0.84. Long-Term Debt to Equity for the company is recorded at 0.51, with the Long-Term Debt to Total Capital now at 0.51.

Reflecting on the efficiency of the workforce at the company, Corcept Therapeutics Incorporated [CORT] managed to generate an average of $457,189 per employee. Receivables Turnover for the company is 16.34 with a Total Asset Turnover recorded at a value of 0.85.Corcept Therapeutics Incorporated’s liquidity data is similarly interesting compelling, with a Quick Ratio of 10.30 and a Current Ratio set at 10.40.

Earnings analysis for Corcept Therapeutics Incorporated [CORT]

With the latest financial reports released by the company, Corcept Therapeutics Incorporated posted 0.22/share EPS, while the average EPS was predicted by analysts to be reported at 0.2/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 10.00%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for CORT.

Insider trade positions for Corcept Therapeutics Incorporated [CORT]

There are presently around $1,787 million, or 78.40% of CORT stock, in the hands of institutional investors. The top three institutional holders of CORT stocks are: BLACKROCK INC. with ownership of 15,884,743, which is approximately 4.198% of the company’s market cap and around 0.30% of the total institutional ownership; VANGUARD GROUP INC, holding 11,239,346 shares of the stock with an approximate value of $224.56 million in CORT stocks shares; and RENAISSANCE TECHNOLOGIES LLC, currently with $178.22 million in CORT stock with ownership of nearly 7.433% of the company’s market capitalization.

Positions in Corcept Therapeutics Incorporated stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 120 institutional holders increased their position in Corcept Therapeutics Incorporated [NASDAQ:CORT] by around 6,330,166 shares. Additionally, 94 investors decreased positions by around 5,223,021 shares, while 39 investors held positions by with 77,908,730 shares. The mentioned changes placed institutional holdings at 89,461,917 shares, according to the latest SEC report filing. CORT stock had 46 new institutional investments in for a total of 1,847,933 shares, while 27 institutional investors sold positions of 1,322,039 shares during the same period.

More articles

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest article

2U Inc. [TWOU] Revenue clocked in at $675.10 million, up 38.64% YTD: What’s Next?

2U Inc. plunged by -$0.63 during the normal trading session on Thursday and reaching a high of $33.8363 during the day while it...

W&T Offshore Inc. [WTI] Is Currently 3.49 above its 200 Period Moving Avg: What Dose This Mean?

W&T Offshore Inc. traded at a high on 09/24/20, posting a 3.49 gain after which it closed the day’ session at $1.78. The...

Tricida Inc. [TCDA] moved down -3.00: Why It’s Important

Tricida Inc. price plunged by -3.00 percent to reach at -$0.28. A sum of 1179796 shares traded at recent session while its average...

TG Therapeutics Inc. [TGTX] Stock trading around $23.74 per share: What’s Next?

TG Therapeutics Inc. loss -3.96% or -0.98 points to close at $23.74 with a heavy trading volume of 2201762 shares. It opened the...

Translate Bio Inc. [TBIO] gain 55.28% so far this year. What now?

Translate Bio Inc. closed the trading session at $12.64 on 09/24/20. The day’s price range saw the stock hit a low of $11.91,...